文献速递肝病

SIRT5 rs12216101 T>G变异与非酒精性脂肪性肝病患者的肝损伤及线粒体功能障碍相关

SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.
PubMed 文献 · J Hepatol · 2023-10-25

在2606例经活检证实的欧洲非酒精性脂肪性肝病患者中,SIRT5 rs12216101 T>G变异与脂肪性肝炎(OR 1.20,95%CI 1.03-1.40)及F2-F4纤维化(OR 1.18,95%CI 1.00-1.37)相关;G等位基因携带者线粒体氧化磷酸化复合物III、IV、V上调,活性氧、活性氮及丙二醛水平更高,ATP水平更低;SIRT5药物抑制可恢复HepG2细胞线粒体能量稳态。

要点

  • 在2606例经活检证实的非酒精性脂肪性肝病患者中,SIRT5 rs12216101 T>G变异与脂肪性肝炎和F2-F4纤维化相关。
  • G等位基因携带者线粒体氧化磷酸化复合物III、IV、V表达上调,活性氧、活性氮和丙二醛水平更高,ATP水平更低。
  • SIRT5药物抑制可恢复暴露于过量游离脂肪酸的HepG2细胞的线粒体能量稳态。

核心结论

  • SIRT5 rs12216101 T>G变异增强SIRT5活性,与非酒精性脂肪性肝病患者的肝损伤、线粒体功能障碍和氧化应激相关。
  • SIRT5 rs12216101 T>G变异与非酒精性脂肪性肝病疾病严重程度更高相关,该风险变异导致SIRT5功能获得,增强线粒体氧化磷酸化并导致氧化应激。
  • SIRT5可能是非酒精性脂肪性肝病的新疾病调节因子。

研究设计与样本

  • 对2606例连续纳入的经活检证实的非酒精性脂肪性肝病欧洲患者进行SIRT5 rs12216101变异基因分型。
  • 对部分减重手术患者的肝样本进行转录组分析、线粒体复合物表达和氧化应激水平检测。
  • 在暴露于过量游离脂肪酸的HepG2细胞中评估SIRT5药物抑制的效果,并通过高效液相色谱研究体外线粒体能量学。

主要发现

  • 全队列中SIRT5 rs12216101 TT、TG和GG基因型频率分别为47.0%、42.3%和10.7%。
  • 校正性别、年龄>50岁、糖尿病和PNPLA3 rs738409状态的多因素logistic回归分析显示,SIRT5 rs12216101 T>G变异与脂肪性肝炎存在相关(OR 1.20,95%CI 1.03-1.40),与F2-F4纤维化存在相关(OR 1.18,95%CI 1.00-1.37)。
  • 转录组分析显示SIRT5 rs12216101 T>G变异与线粒体代谢通路(包括氧化磷酸化系统)转录本上调相关。
  • 在G等位基因携带者中,蛋白质印迹分析证实氧化磷酸化复合物III、IV、V上调,并伴有活性氧、活性氮和丙二醛水平更高及ATP水平更低。
  • 给予SIRT5药物抑制剂可维持HepG2细胞的线粒体能量稳态,表现为ATP/ADP、NAD+/NADH、NADP+/NADPH比值和谷胱甘肽水平恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Sirtuin 5, encoded by the SIRT5 gene, is a NAD+-dependent deacylase that modulates mitochondrial metabolic processes through post-translational modifications. In this study, we aimed to examine the impact of the SIRT5 rs12216101 T>G non-coding single nucleotide polymorphism on disease severity in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: The rs12216101 variant was genotyped in 2,606 consecutive European patients with biopsy-proven NAFLD. Transcriptomic analysis, expression of mitochondrial complexes and oxidative stress levels were measured in liver samples from a subset of bariatric patients. Effects of SIRT5 pharmacological inhibition were evaluated in HepG2 cells exposed to excess free fatty acids. Mitochondrial energetics in vitro were investigated by high-performance liquid chromatography. RESULTS: In the whole cohort, the frequency distribution of SIRT5 rs12216101 TT, TG and GG genotypes was 47.0%, 42.3% and 10.7%, respectively. At multivariate logistic regression analysis adjusted for sex, age >50 years, diabetes, and PNPLA3 rs738409 status, the SIRT5 rs12216101 T>G variant was associated with the presence of non-alcoholic steatohepatitis (odds ratio 1.20, 95% CI 1.03-1.40) and F2-F4 fibrosis (odds ratio 1.18; 95% CI 1.00-1.37). Transcriptomic analysis showed that the SIRT5 rs12216101 T>G variant was associated with upregulation of transcripts involved in mitochondrial metabolic pathways, including the oxidative phosphorylation system. In patients carrying the G allele, western blot analysis confirmed an upregulation of oxidative phosphorylation complexes III, IV, V and consistently higher levels of reactive oxygen species, reactive nitrogen species and malondialdehyde, and lower ATP levels. Administration of a pharmacological SIRT5 inhibitor preserved mitochondrial energetic homeostasis in HepG2 cells, as evidenced by restored ATP/ADP, NAD+/NADH, NADP+/NADPH ratios and glutathione levels. CONCLUSIONS: The SIRT5 rs12216101 T>G variant, heightening SIRT5 activity, is associated with liver damage, mitochondrial dysfunction, and oxidative stress in patients with NAFLD. IMPACT AND IMPLICATIONS: In this study we discovered that the SIRT5 rs12216101 T>G variant is associated with higher disease severity in patients with non-alcoholic fatty liver disease (NAFLD). This risk variant leads to a SIRT5 gain-of-function, enhancing mitochondrial oxidative phosphorylation and thus leading to oxidative stress. SIRT5 may represent a novel disease modulator in NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Salomone F, Pipitone RM, Longo M, et al. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease. J Hepatol. 2023. PMID: 37890719. doi:10.1016/j.jhep.2023.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。